Journal
MOLECULAR ONCOLOGY
Volume 1, Issue 1, Pages 42-54Publisher
WILEY
DOI: 10.1016/j.molonc.2007.01.003
Keywords
Antibody; Cancer; CD20; Cytotoxicity; Hybridoma; Therapy
Categories
Funding
- National Cancer Institute
- Israel Science Foundation
- Israel Cancer Research Fund
- Prostate Cancer Foundation
- German-Israel Foundation
Ask authors/readers for more resources
Ten years after the first clinical application of Rituximab, an anti-CD20 recombinant monoclonal antibody, immunotherapy has become common practice in oncology wards. Thanks to the great diversity of the immune system and the powerful methodology of genetic engineering, the pharmacologic potential of antibody-based therapy is far from exhaustion. The recent application of Trastuzumab, an antibody to a receptor tyrosine kinase, in adjuvant breast cancer therapy marks the beginning of a new phase in cancer treatment. Here we discuss molecular mechanisms of antibody-based therapy, the emerging ability to target minimal disease and the therapeutic potential of combining antibodies with other modalities. (C) 2007 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available